Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 15/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1947497 | 0.83 | IDO1 (0.70) | IDO1CYP3A4 | |
| SCHEMBL1948725 | 0.79 | IDO1 (1.00) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL1948734 | 0.74 | IDO1 (0.69) | IDO1CYP3A4CYP2D6 | |
| SCHEMBL26259992 | 0.74 | ADRA2A (0.66) | IDO1CYP3A4CYP2E1CYP2D6CYP2A6 | |
| SCHEMBL1904102 | 0.73 | IDO1 (0.55) | IDO1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7194641 | 0.71 | IDO1 (0.59) | IDO1CYP3A4CYP2E1CYP2D6CYP2A6 | |
| SCHEMBL25262025 | 0.71 | IDO1 (0.64) | IDO1CYP3A4CYP2E1CYP2D6CYP2A6 | |
| SCHEMBL12075152 | 0.70 | IDO1 (0.54) | IDO1CYP3A4CYP2E1CYP2D6CYP2A6 | |
| SCHEMBL26259980 | 0.70 | IDO1 (0.64) | IDO1CYP3A4CYP2E1CYP2D6CYP2A6 | |
| SCHEMBL1949904 | 0.69 | IDO1 (0.65) | IDO1CYP3A4ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | claimed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | claimed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | claimed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323740-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 250/4885CYP2E1 234/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 250/4885CYP2E1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.